A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...

TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...

Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

Please provide your email address to receive an email when new articles are posted on . IL-13, which dupilumab blocks, induces nitric oxide production, which leads to mucus hypersecretion. At week 24, ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

Confirmatory data to support U.S. regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than ...

In a new clinical practice guideline, recommendations are presented to optimize the use of biologic agents for severe asthma in adults.

FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade Safety results in all LIBERTY-CUPID Phase 3 trials were generally consistent with ...

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Approximately half of patients do not respond to H1 ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Regeneron/Sanofi) for the treatment of eosinophilic esophagitis (EoE) in children aged 1-11 years and weighing ≥ 15 kg. It ...

This study enhances current understandings of dupilumab use in patients with atopic dermatitis (AD) by showing its real-world effectiveness and safety. Dupilumab is an effective and safe treatment ...